



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / مني مغربي أحمد

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد





Ain Shams University
Faculty of Science
Department of Biochemistry



Molecular Analysis of Induced Leukemia in Mice Treated with a Novel Bithiophene Derivative

A thesis

*Submitted as a partial fulfillment for the requirements of the
Master's Degree in Biochemistry*

Ali Mohamed Samy Al-gharib

(B.Sc. of Biochemistry, ٢٠١٥)

Under the Supervision of

Prof. Dr. Gamila Mohamed Labib Shanab

Professor of Biochemistry

Faculty of Science

Ain Shams University

Prof. Dr. Abdel-Rahman Badreldeen Abdel-Ghaffar

Professor of Biochemistry

Faculty of Science

Ain Shams University

Dr. Rania Hassan Mohammed

Lecturer of Biochemistry

Faculty of Science

Ain Shams University

Biography

Name: Ali Samy Al-gharib

Date of Graduation: ٢٠١٥

Degree awarded: B.Sc. of Biochemistry/Chemistry
(Excellent with Honor Degree)

Occupation: Teaching Assistant
Biochemistry Department
Faculty of Science
Ain Shams University

Declaration

I declare that this thesis and the work presented in it are my own and has been generated by me as the result of my own original research.

Ali Samy Al-gharib

ACKNOWLEDGEMENTS

I would like to take this opportunity to express my heartfelt gratitude to all those who helped me to make my thesis successful.

***First of all, I would like to thank Allah** who has given me the strength to be dedicated to my work and contribute my best to it so that it turns out to be a successful thesis.*

I would like to express my deepest gratitude to:

***Dr. Gamila Shanab Professor of Biochemistry, Faculty of Science, Ain Shams University** for her valuable guidance, technical and moral support given to me throughout the entire dissertation,*

***Dr. Abdel-Rahman B. Abdel-Ghaffar Professor of Biochemistry, Faculty of Science, Ain Shams University** for his regular advice, marvelous guidance, suggestions and encouragement throughout my research.*

***Dr. Rania Hassan Mohamed Lecturer of Biochemistry, Faculty of Science, Ain Shams University** for her endless help, precise revision of the results and discussion of the manuscript, and invaluable assistance, encouragement, inspiring advice and moral support in carrying out this dissertation. I thank her from the bottom of my heart for mentoring my professional endeavors. She has been a constant source of inspiration and has always encouraged scientific thinking and instilled me a sense of discipline in my work.*

I would also like to express my heartfelt thanks to:

*Dr. Wael Mohamed Elsayed, Professor of Physiology,
Department of Zoology, Faculty of Science, Ain Shams
University*

*Dr. Mohamed Ismail, Professor of Organic Chemistry,
Department of Chemistry, Faculty of Science, Mansoura
University, for providing the novel compound.*

*Dr Sayed Abdel Raheem, Assistant Professor of
Histopathology, Faculty of Medicine, AlAzhar University
for boys, for his assistance in the histopathological study.*

*Dr Samer Abbas, Professor of Clinical Pathology, Faculty
of Medicine, Ain Shams University, for the assistance with the
pathological study.*

*There are no words to express my gratitude and thanks to my
beloved parents, family members and friends, for always
standing by me. Their love has been the major spiritual support in
my life.*

*As a final word, I would like to thank each and every individual
who have been a source of support and encouragement and
helped me to achieve my goal and complete my dissertation work
successfully.*

Ali Samy Al-gharib

Contents

Subject	Page No.
List of Tables	III
List of Figures	IV
List of abbreviations	IX
Abstract	۱
Introduction	۳
Aim of the work	۷
Review of Literature	۸
Hematopoiesis	۸
Leukemia	۱۰
۷,۱۲-Dimethylbenz[a]anthracene (DMBA)	۱۴
Bithiophene	۱۷
Fluorophenyl bithiophene derivative	۲۴
<i>In vitro</i> antiproliferative screening	۲۴
DNA affinity and nuclease-like activity	۲۶
Antioxidant activity	۲۶
Cell cycle	۲۷
Role of AKT pathway & PTEN in AML	۳۱
Material and methods	۳۹
Experimental animals	۳۹
Chemicals	۴۰
Experimental Design	۴۱
Hematological Measurements	۴۲
Blood smear	۴۲
Bone marrow smear	۴۳
Histopathological Examination	۴۳
Body weight change calculation	۴۵
Calculation of the relative organs weights	۴۶
Molecular Analysis	۴۶
Immunoblotting investigation (Western blot)	۴۶

Gene expression.....	xi
----------------------	----

Quantitative estimation of p ^{٥٣} by ELISA	٥٧
Quantitative estimation of Cyclin dependent kinase λ (CDK λ) by ELISA.....	٦١
Quantitative estimation of Cyclin dependent kinase inhibitor λ A (CDKN λ A/p λ) by ELISA	٦٤
Determination of bone marrow Caspase- λ activity	٦٧
Statistical analysis	٧١
Results	٧٢
Relative organs weight & body weight change	٧٢
Hematological studies	٧٧
Histological studies	٨٢
Molecular analysis	١٠٤
Detection of AKT & PTEN protein expression	١٠٤
p ^{٥٣} expression levels.....	١٠٧
CDK λ expression levels.....	١٠٩
CDKN λ A/p λ expression levels.....	١١١
Bone marrow caspase- λ activity.....	١١٣
Discussion	١١٤
Summary	١٢١
Conclusions & Recommendations	١٢٥
References	١٢٧
Appendix	
المستخلص العربي.....	
الملخص العربي	

List of Tables

Table (1,1): CDKs/cyclins in cell	
Table (2,1): Components of cDNA master mix	
Table (2,2): Primers used for	
Table (2,3): Real time-PCR reaction components.....	57
Table (2,4): Thermal cycling conditions.....	57
Table (3,1): Effect of the treatment on the relative weights of liver and spleen.....	74
Table (3,2): Effect of the treatment on the bone marrow hematological cells count.....	78
Table (3,3): Effect of treatment on WBCs, RBCs, Platelets counts and Hb content on DMBA-treated mice..	81
Table (3,4): Summary of the histologic abnormalities in liver hepatocytes of the different studied groups.....	93
Table (3,5): Summary of the histologic abnormalities in spleen of the different studied groups.....	103

List of Figures

Fig. 1,1: Development of different blood cells from hematopoietic stem cell to mature cells.....	9
Fig. 1,2: Normal and leukemic blood smears images.....	10
Fig. 1,3: Structure of 1,2-Dimethylbenz[a]anthracene (DMBA).....	10
Fig. 1,4: Metabolic pathway for potential DMBA bioactivation via CYP1B1 and mEH.....	17
Fig. 1,5: Thiophene.....	18
Fig. 1,6: Drugs in markets comprising thiophene nucleus.....	20
Fig. 1,7: Bithiophene diamidines.....	22
Fig. 1,8: diamidinophenylbithiophene.....	22
Fig. 1,9: Antitumor activities of different thiophene based compounds.....	23
Fig. 1,10: Monocationic bithiophene.....	24
Fig. 1,11: Structure of the novel Bithienyl fluorobenzamidine derivative.....	25
Fig. 1,12: A schematic diagram of the cell cycle, showing phases regulated by cyclin-dependent kinases (CDKs) and their cyclins, and CDK inhibitors.....	31
Fig. 1,13: Cellular Functions of Akt Substrates.....	34

Fig. 1, 14: Significance of various feedback loops involving the PTEN-AKT-p ³⁸ -MDM ² regulatory network.....	36
Fig. 2, 1: Schematic diagram for experimental design.....	40
Fig. 2, 2: Standard curve of p ³⁸	60
Fig. 2, 3: Schematic diagram of the mouse CDK ¹ ELISA kit.....	61
Fig. 2, 4: Standard curve of CDK ¹	64
Fig. 2, 5: Standard curve of p ²¹	67
Fig. 2, 6: Standard curve of Caspase 3.....	70
Fig. 3, 1: Effect of the treatment on the body weight gain.....	73
Fig. 3, 2: Effect of the treatment on the relative weights of liver.....	75
Fig. 3, 3: Effect of the treatment on the relative weights of spleen.....	76
Fig. 3, 4: Effect of the treatment on the bone marrow hematological cells count.....	79
Fig. 3, 5: A photomicrograph of liver section of normal healthy Mice.....	82
Fig. 3, 6: A photomicrograph of liver section of positive control leukemic mice.....	83
Fig. 3, 7: A photomicrograph of liver section of positive control leukemic mice.....	84

Fig. ٣, ٨: A photomicrograph of liver section of positive control leukemic mice.....	٨٤
Fig. ٣, ٩: A photomicrograph of liver section of positive control leukemic mice.....	٨٥
Fig. ٣, ١٠: A photomicrograph of liver section of leukemic mice treated with ١\٥ LD _{٥٠} of BFB.....	٨٦
Fig. ٣, ١١: A photomicrograph of liver section of leukemic mice treated with ١\٥ LD _{٥٠} of BFB.....	٨٧
Fig. ٣, ١٢: A photomicrograph of liver section of leukemic mice treated with ١\٥ LD _{٥٠} of BFB.....	٨٧
Fig. ٣, ١٣: A photomicrograph of liver section of leukemic mice treated with ١\٥ LD _{٥٠} of BFB.....	٨٨
Fig. ٣, ١٤: A photomicrograph of liver section of leukemic mice treated with ١\١٠ LD _{٥٠} of BFB.....	٨٩
Fig. ٣, ١٥: A photomicrograph of liver section of BFB-control mice receiving ١\٥ LD _{٥٠} dose.....	٩٠
Fig. ٣, ١٦: A photomicrograph of liver section of BFB-control mice receiving ١\٥ LD _{٥٠} dose.....	٩٠
Fig. ٣, ١٧: A photomicrograph of liver section of BFB-control mice receiving ١\١٠ LD _{٥٠} dose.....	٩١
Fig. ٣, ١٨: A photomicrograph of liver section of BFB-control mice receiving ١\١٠ LD _{٥٠} dose.....	٩٢
Fig. ٣, ١٩: A photomicrograph of spleen section of normal healthy mice.....	٩٤

Fig. 3,20: A photomicrograph of spleen section of positive control leukemic mice.....	90
Fig. 3,21: A photomicrograph of spleen section of positive control leukemic mice.....	96
Fig. 3,22: A photomicrograph of spleen section of positive control leukemic mice.....	96
Fig. 3,23: A photomicrograph of spleen section of leukemic mice treated with 10 LD50 of BFB.....	97
Fig. 3,24: A photomicrograph of spleen section of leukemic mice treated with 10 LD50 of BFB.....	98
Fig. 3,25: A photomicrograph of spleen section of leukemic mice treated with 10 LD50 of BFB.....	98
Fig. 3,26: A photomicrograph of spleen section of leukemic mice treated with 10 LD50 of BFB.....	99
Fig. 3,27: A photomicrograph of spleen section of leukemic mice treated with 10 LD50 of BFB.....	100
Fig. 3,28: A photomicrograph of spleen section of control mice receiving 10 LD50 dose.....	101
Fig. 3,29: A photomicrograph of spleen section of control mice receiving 10 LD50 dose.....	101
Fig. 3,30: A photomicrograph of spleen section of control mice receiving 10 LD50 dose.....	102

Fig. 3,31: Expression of pAKT in the bone marrow of normal healthy group and experimental groups.....	100
Fig. 3,32: Expression of PTEN in the bone marrow of normal healthy group and experimental groups.....	106
Fig. 3,33: A) represents bone marrow p ³³ gene expression B) represents bone marrow p ³³ protein levels, respectively in all studied groups as compared to normal healthy group.....	108
Fig. 3,34: A) represents bone marrow CDK ¹ gene expression B) represents bone marrow CDK ¹ protein levels, respectively in all studied groups as compared to normal healthy group.....	110
Fig. 3,35: A) represents bone marrow p ³⁷ gene expression B) represents bone marrow p ³⁷ protein levels, respectively in all studied groups as compared to normal healthy group.....	112
Fig. 3,36: Caspase-3 protein levels in experimental groups compared to normal healthy group.....	113
Fig. 4,1: Proposed molecular effect of Bithienyl fluorobenzamide as a treatment against DMBA-induced leukemia.....	126